logo
Plus   Neg
Share
Email

Teva Pharmaceutical Remains Firmly Negative After Early Sell-Off

After falling sharply early in the session, shares of Teva Pharmaceutical Industries Ltd. (TEVA) continue to see significant weakness in afternoon trading on Wednesday. Teva is currently down by 4.9 percent after moving higher for three straight sessions.

The pullback by Teva comes after a report from Reuters said pharmacy benefits manager Express Scripts Holding Co. (ESRX) will cover new migraine drugs from Eli Lilly & Co. (LLY) and Amgen Inc. (AMGN) but is excluding a rival medication made by Teva.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT